Colorectal Cancer
📧 Sign up to get email alerts when something new happens for Colorectal Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-08Clinical Trial Update: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER [Phase 1, Phase 2]
A Phase 1/2 clinical trial at Massachusetts General Hospital is evaluating how coffee and its metabolites affect the gut microbiome in color…
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]
The Phase 1/2 trial of surufatinib in combination with tislelizumab for advanced solid tumors has been terminated. Results were posted on 20…
-
CLINICAL_TRIALS research · 2025-05-08Clinical Trial Update: Predicting Cancer Risk With Digital and Molecular Markers [NA]
A University of Erlangen-Nürnberg Medical School trial aims to predict cancer risk using digital and molecular markers across several cancer…
-
CLINICAL_TRIALS research · 2025-05-08Clinical Trial Update: Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
A clinical trial sponsored by the University of Michigan Rogel Cancer Center is evaluating stool-based markers for the early detection of co…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. [NA]
This is a prospective study (EQUITY GI) to improve quality, inclusivity, and trial participation for Black patients with gastrointestinal ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy [Phase 4]
Phase 4 clinical trial comparing Huaier extract with capecitabine monotherapy for prevention of recurrence and metastasis in colorectal canc…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer [Phase 2]
A Phase 2 study of cetuximab as third-line therapy for refractory metastatic colorectal cancer with APC, TP53, and RAS mutations was termina…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption [Phase 2]
A Phase 2 clinical trial completed an evaluation of changes in colonic microbiota after energy drink consumption in colorectal cancer patien…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: NeoRes Study - Preoperative Chemotherapy in Colorectal Peritoneal Disease Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Clinical trial update on the NeoRes study evaluating preoperative systemic chemotherapy for colorectal cancer with peritoneal metastases pri…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Effect of Malignancy on Morbidity and Mortality in Left-sided Emergency Colorectal Resections
This clinical trial evaluated whether malignancy influences morbidity and mortality after left-sided emergency colorectal resections; the st…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI's Pan-tumor Priority Study is an observational cancer study that is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer [Phase 2]
Phase 2 trial investigating danvatirsen in combination with durvalumab for advanced and refractory colorectal cancer, pancreatic cancer, and…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care [NA]
A completed clinical trial from the University of Florida evaluated a technology-based, patient-centered intervention to reduce colorectal c…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer [Phase 2]
Phase 2 clinical trial evaluating IBI351 with cetuximab beta plus FOLFIRI as first-line and cetuximab beta alone as second-line therapy for …
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating the efficacy and safety of Envafolimab in combination with Cetuximab and the mFOLFOX6 regimen in patie…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Tempus CRC Surveillance Study is a ctDNA biomarker profiling study in colorectal cancer patients using next-generation sequencing assays. Th…
-
EMA approval · 2025-05-05EMA Authorised: Capecitabine Accord (capecitabine) — Accord Healthcare S.L.U.
The EMA authorised Capecitabine Accord (capecitabine) by Accord Healthcare S.L.U. for breast cancer, colorectal cancer, and stomach cancer, …
-
EMA approval · 2025-05-05EMA Authorised: Ecansya (previously Capecitabine Krka) (capecitabine) — Krka, d.d., Novo mesto
The EMA authorised Ecansya, a capecitabine product by Krka, as a new generic cancer treatment option for breast, colon, colorectal, and gast…
-
CLINICAL_TRIALS trial_result · 2025-05-04Clinical Trial Update: Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening [NA]
Completed clinical trial evaluating the use of financial incentives to improve colorectal cancer screening engagement; results have been pos…
-
CLINICAL_TRIALS research · 2025-05-04Clinical Trial Update: Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes [Phase 2]
Phase 2 trial assessing a hydroxychloroquine-based combination against regorafenib for refractory metastatic colorectal cancer with RAS muta…
-
EMA approval · 2025-05-02EMA Authorised: Xeloda (capecitabine) — CHEPLAPHARM Arzneimittel GmbH
The EMA authorised CHEPLAPHARM Arzneimittel GmbH to market Xeloda (capecitabine) in the EU for several cancers, including breast, colon/colo…
-
EMA approval · 2025-05-02EMA Authorised: Capecitabine Medac (capecitabine) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised Capecitabine Medac for colorectal cancer. Medac Gesellschaft für klinische Spezialpräparate mbH is the marketing authorizatio…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Screening With a DNA Blood Test to Address Colorectal Cancer Inequities [NA]
A ClinicalTrials.gov update describes a study evaluating a DNA blood test for colorectal cancer screening aimed at addressing inequities, cu…
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer [Phase 1, Phase 2]
Esperas Pharma completed a Phase 1/2 study of LY2880070 in adults with advanced or metastatic cancer, including colorectal cancer.
-
CLINICAL_TRIALS trial_result · 2025-05-01Clinical Trial Update: Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
A completed clinical trial comparing Tirellizumab plus Anlotinib versus Anlotinib alone in microsatellite-stable colorectal cancer.